Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of a liquid allergy vaccine formulation for oromucosal administration

A liquid vaccine and oral mucosa technology, applied in the field of allergic vaccine preparations, can solve problems such as side effects and polyreactivity that cannot be excluded, and achieve the effects of simple administration scheme and increased treatment compliance

Inactive Publication Date: 2009-01-07
ALK ABELLO SA
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Second, transmission of the offending allergen occurs most frequently, leading to allergic polyreactivity
However, such a pulse escalation therapy has a disadvantage: the occurrence of serious side effects cannot be ruled out and thus, like subcutaneous administration, it requires the supervision of an allergist specialist

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of a liquid allergy vaccine formulation for oromucosal administration
  • Use of a liquid allergy vaccine formulation for oromucosal administration
  • Use of a liquid allergy vaccine formulation for oromucosal administration

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0083] Example 1: Sublingual immunotherapy (SLIT) without dose escalation - new treatment options

[0084] introduction

[0085] Over the past few years, several studies have been conducted using sublingual immunotherapy (SLIT) generating evidence of efficacy combined with a favorable safety profile (1).

[0086] In order for patients to obtain high levels of self-administered therapies such as effect, the compliance must be high (2). Given that the basis for compliance is convenience, it is relevant to enhance this property of the product. The excellent tolerability of SLIT has led to consideration of eliminating the possibility of increasing dose periods. This would improve patient convenience, which could increase compliance and potentially increase treatment efficiency. This study is designed to evaluate Tolerability in patients with mite or grass sensitization without dose escalation.

[0087] Materials and methods

[0088] potion

[0089] SLITone (ALK-A...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the use of an allergen for the manufacture of a liquid vaccine formulation for preventing or treating allergy in a subject by oromucosal administration in a dosage regimen comprising no up-dosing.

Description

technical field [0001] The present invention relates to allergy vaccine formulations for oromucosal administration. Background of the invention [0002] Allergies are a serious health problem in countries adapted to a western lifestyle. Furthermore, the prevalence of allergic diseases is increasing in these countries. Although allergies are not generally considered a life-threatening disease, asthma is responsible for a significant number of deaths each year. The abnormal prevalence of approximately 30% among adolescents causes significant losses in quality of life, workdays and money, thereby becoming a class of serious health problems in Western countries. [0003] Allergies are complex diseases. Many factors contribute to sensitization events. One of these factors is an individual's susceptibility determined by the interaction between several genes that have not yet been fully understood. Another important factor is exposure to allergens above certain thresholds. Se...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/00A61K47/02A61K47/10A61K39/35A61K39/36A61P37/08
Inventor D·B·赫尔南德兹F·D·L·T·玛丁内兹P·R·涅图
Owner ALK ABELLO SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com